Zogenix Risk Management Strategy For Zohydro ER Includes Capping Sales Rep Compensation
This article was originally published in The Pink Sheet Daily
Executive Summary
Abuse potential of the single-entity hydrocodone will be key factor during the Anesthetic and Analgesic Drugs Products Advisory Committee’s review, and the company is hoping to allay those concerns by offering promotional restrictions and a Risk Evaluation and Mitigation Strategy stricter than the one for extended-release/long-action opioids.